We are live on ! Find out more
ITOS

iTeos Therapeutics
ITOS

Delisted

ITOS was delisted on the 28th of August, 2025.

Back to rankings

153 hedge funds and large institutions have $489M invested in iTeos Therapeutics in 2023 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 57 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 17

5% more funds holding

Funds holding: 146 → 153 (+7)

1.01% less ownership

Funds ownership: 101.74% → 100.73% (-1%)

21% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 57

31% less capital invested

Capital invested by funds: $704M → $489M (-$215M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

66% less call options, than puts

Call options by funds: $322K | Put options by funds: $948K

Holders
153
Holders Change
+7
Holders Change %
+4.79%
% of All Funds
2.44%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
25
Increased
45
Reduced
57
Closed
17
Calls
$322K
Puts
$948K
Net Calls
-$626K
Net Calls Change
-$1.18M

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$5.91M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$4.49M
3
OCA
Octagon Capital Advisors
New York
+$2.71M
4
SVCM
Saturn V Capital Management
Texas
+$2.48M
5
State Street
State Street
Massachusetts
+$1.61M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$6.2M
2
Bank of America
Bank of America
North Carolina
-$5.64M
3
Morgan Stanley
Morgan Stanley
New York
-$5.08M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.55M
5
AP
Advisors Preferred
Maryland
-$1.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$3.57M -$222K -12,418 -5%
Barclays
27
Barclays
United Kingdom
$3.5M +$35.7K +1,995 +0.8%
Northern Trust
28
Northern Trust
Illinois
$3.43M -$29.9K -1,668 -0.7%
Axa
29
Axa
France
$2.98M -$8.89K -496 -0.2%
TCM
30
Tang Capital Management
California
$2.95M – – –
Fidelity Investments
31
Fidelity Investments
Massachusetts
$2.9M -$2.55M -142,283 -40%
Charles Schwab
32
Charles Schwab
California
$2.49M +$8.55K +477 +0.3%
IHAM
33
Integral Health Asset Management
New York
$2.45M -$1.61M -90,000 -33%
AQR Capital Management
34
AQR Capital Management
Connecticut
$2.41M -$457K -25,521 -13%
Bank of America
35
Bank of America
North Carolina
$2.15M -$5.64M -314,885 -67%
Prudential Financial
36
Prudential Financial
New Jersey
$2.14M +$202K +11,300 +8%
Principal Financial Group
37
Principal Financial Group
Iowa
$2.11M -$59.7K -3,331 -2%
BBA
38
Baker Bros. Advisors
New York
$2.05M – – –
Wellington Management Group
39
Wellington Management Group
Massachusetts
$2.02M -$35K -1,953 -1%
Ameriprise
40
Ameriprise
Minnesota
$1.89M +$298K +16,653 +14%
PAM
41
Panagora Asset Management
Massachusetts
$1.59M +$1.19M +66,303 +131%
Rafferty Asset Management
42
Rafferty Asset Management
New York
$1.55M +$204K +11,384 +11%
LP
43
LMR Partners
United Kingdom
$1.54M +$1.48M +82,700 +274%
Los Angeles Capital Management
44
Los Angeles Capital Management
California
$1.46M +$341K +19,024 +22%
American Century Companies
45
American Century Companies
Missouri
$1.45M -$1.12M -62,416 -36%
DCM
46
DAFNA Capital Management
California
$1.34M – – –
N
47
Nuveen
North Carolina
$1.32M +$141K +7,854 +9%
SAM
48
Sectoral Asset Management
Quebec, Canada
$1.2M +$548K +30,611 +53%
Vontobel Holding
49
Vontobel Holding
Switzerland
$1.2M +$548K +30,611 +53%
Victory Capital Management
50
Victory Capital Management
Texas
$1.15M +$374K +20,857 +33%
1
2
3 4 5

ITOS Hedge Fund Activity: Q1 2023 in Review

153 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q1 2023, worth a combined $489M — down 31% from $704M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ITOS positions and 17 closed out — a net gain of 8 holders — while 45 added to existing stakes and 57 trimmed.

The largest buyer was 683 Capital Management, adding an estimated $5.91M. The largest seller was Millennium Management, cutting an estimated $6.2M.

  • 153 institutional investors held iTeos Therapeutics (ITOS) as of Q1 2023, up from 146 in Q4 2022.
  • Funds reported $489M of iTeos Therapeutics stock for Q1 2023, down 31% quarter-over-quarter.
  • 25 funds opened new iTeos Therapeutics positions in Q1 2023 and 17 closed out, a net change of +8 holders.
  • The largest iTeos Therapeutics buyer in Q1 2023 was 683 Capital Management, an estimated $5.91M added.
  • The largest iTeos Therapeutics seller in Q1 2023 was Millennium Management, an estimated $6.2M sold.

Based on aggregated 13F filings for Q1 2023.